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A case of fatal Type I congenital disorders
of glycosylation (CDG I) associated with
low dehydrodolichol diphosphate
synthase (DHDDS) activity
S. Sabry1,2,3,4, S. Vuillaumier-Barrot1,2,5, E. Mintet1,2, M. Fasseu1,2, V. Valayannopoulos6, D. Héron7,8, N. Dorison8,
C. Mignot7,8,9, N. Seta5,10, I. Chantret1,2, T. Dupré1,2,5 and S. E. H. Moore1,2*
Abstract
Background: Type I congenital disorders of glycosylation (CDG-I) are mostly complex multisystemic diseases
associated with hypoglycosylated serum glycoproteins. A subgroup harbour mutations in genes necessary for
the biosynthesis of the dolichol-linked oligosaccharide (DLO) precursor that is essential for protein N-glycosylation.
Here, our objective was to identify the molecular origins of disease in such a CDG-Ix patient presenting with axial
hypotonia, peripheral hypertonia, enlarged liver, micropenis, cryptorchidism and sensorineural deafness associated
with hypo glycosylated serum glycoproteins.
Results: Targeted sequencing of DNA revealed a splice site mutation in intron 5 and a non-sense mutation in exon
4 of the dehydrodolichol diphosphate synthase gene (DHDDS). Skin biopsy fibroblasts derived from the patient
revealed ~20 % residual DHDDS mRNA, ~35 % residual DHDDS activity, reduced dolichol-phosphate, truncated
DLO and N-glycans, and an increased ratio of [2-3H]mannose labeled glycoprotein to [2-3H]mannose labeled DLO.
Predicted truncated DHDDS transcripts did not complement rer2-deficient yeast. SiRNA-mediated down-regulation
of DHDDS in human hepatocellular carcinoma HepG2 cells largely mirrored the biochemical phenotype of cells
from the patient. The patient also harboured the homozygous ALG6(F304S) variant, which does not cause CDG
but has been reported to be more frequent in PMM2-CDG patients with severe/fatal disease than in those with
moderate presentations. WES did not reveal other strong candidate causal genes.
Conclusions: We describe a patient presenting with severe multisystem disease associated with DHDDS deficiency.
As retinitis pigmentosa is the only clinical sign in previously reported cases, this report broadens the spectrum of
phenotypes associated with this condition.
Keywords: Protein N-glycosylation, Dolichol linked oligosaccharide, Retinitis pigmentosa, Endoplasmic reticulum
Background
Type I congenital disorders of glycosylation (CDG-I) are
rare inborn errors in metabolism A subgroup of CDG-I
is caused by mutations in genes involved in the biosyn-
thesis of the dolichol linked oligosaccharide (DLO)
precursor required for protein N-glycosylation [1]. DLO
is synthesized by a series of reactions, known as the
dolichol cycle (Fig. 1), in which dolichol phosphate
(DolP) is glycosylated with nucleotide sugars and DolP-
sugars, to yield the mature DLO, Glc3Man9GlcNAc2-PP-
dolichol [2, 3]. The sugar moiety of this donor is trans-
ferred from DLO onto nascent polypeptides by oligosac-
charyltransferase (OST) while the byproduct of this
reaction, dolichol-diphosphate (DolPP), is recycled by a
complex process requiring DolPP phosphatase (DOLPP1)
[2, 3]. A lack of mature DLO provokes protein hypogly-
cosylation. In addition to being recycled during protein N-
glycosylation, DolP is synthesized as one of the end
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products of the mevalonate pathway (Fig. 1). In the first
committed step of dolichol biosynthesis the enzyme cis-
prenyltransferase (dehydrodolichol diphosphate synthase:
DHDDS) that forms a complex with the Nogo-B receptor
(NgBR) elongates a farnesyl diphosphate residue by
addition of several isopentenyl moieties derived from
isopentenyl diphosphate to yield dehydrodolichol diphos-
phate [4]. After dephosphorylation of dehydrodolichol
diphosphate by poorly characterized enzymes, the resul-
ting dehydrodolichol is reduced by polyprenolreductase
(dehydrodolichol reductase or steroid 5α-reductase type 3:
SDR5A3) to yield dolichol (Dol) [5] that is subsequently
phosphorylated by dolichol kinase (DOLK) to yield DolP
(Fig. 1). Dolichol kinase deficiency (DOLK-CDG:
MIM610768) presents with hypoglycosylated serum glyco-
proteins, cardiac myopathy, muscular hypotonia and
ichthyosiform dermatitis [6, 7]. Patients with mutations in
polyprenolreductase (SDR5A3-CDG: MIM 612379)
display hypoglycosylated serum glycoproteins, develop-
mental delay, ataxia, visual impairment (optic nerve
atrophy, retinal coloboma, cataract, glaucoma), liver dys-
function, coagulation abnormalities and ichthyosiform
dermatitis [5, 8, 9]. NGBR-CDG patients present with
scoliosis, neurological impairment, refractory epilepsy,
ocular deficits, and visual impairment [10]. By contrast,
DHDDS-CDG patients (MIM 613861) have so far not
presented with hypoglycosylated serum glycoproteins and
clinical signs are limited to retinitis pigmentosa [11, 12].
In the present report we describe biochemical findings in
a fatal case of CDG-I in which mutations in DHDDS were
found. Two mutations leading to 80 % reduction in
DHDDS mRNA were identified. Skin biopsy fibroblasts
revealed variable amounts of truncated DLO and N-gly-
cans, 35 % residual DHDDS activity, reduced DolP, and
down-regulation of DHDDS in HepG2 cells leads to trun-
cated DLO. While whole exome sequencing confirmed
the presence of the DHDDS mutations, it did not reveal
strong alternative candidate genes involved in protein N-
glycosylation.
Methods
Patient
The boy was the first child of non-consanguineous
parents. During pregnancy intra-uterine growth retar-
dation and decreased fetal movements were noted. He
was born at 37 weeks of gestation with a weight of
2090 g (−3.25 SD), a length of 42 cm (−4 SD), an occit-
piofrontal circumference of 32 cm (−2 SD) and Apgar
score 10/10. He had two episodes of severe bradycardia
during his first day of life and was transferred to an
intensive care unit. At clinical examination, the patient
had axial hypotonia, peripheral hypertonia, enlarged
liver, micropenis and cryptorchidism. He had a transient
increase of serum transaminases, renal failure and deve-
loped epilepsy. Liver sonography revealed mild dilatation
of the biliary duct. During his short life, the boy made
little psychomotor acquisitions, had no eye contact, poor
sucking with frequent regurgitations and failure to
thrive. At 2 months, the fundus oculi displayed pale
papillae and the electroretinogram showed no response
to any type of stimulation. Brainstem evoked auditory
potentials showed sensorineural deafness with an audi-
tory threshold of 90 dB (right ear) and 100 dB (left ear).
The patient died at 8 months during a status epilepticus.
Fig. 1 De novo dolichol biosynthesis and the dolichol cycle.
a Dolichol-phosphate (DolP) is synthesized from farnesyl diphosphate
and isopentenyl diphosphate by enzymes encoded by genes indicated
in bold capital letters. Enzymes responsible for the dephosphorlylation
of dehydrodolichol diphosphate have not been characterised. During
the dolichol cycle an oligosaccharide is constructed on DolP by the
sequential transfer of sugars (N-acetylglucosamine; blue squares,
mannose; green circles, glucose; blue circles) by glycosyltransferases and
accessory proteins encoded by genes indicated on the left of the cycle
in bold capital letters. The oligosaccharide Glc3Man9GlcNAc2 is
transferred onto protein (−N-X-S/T-) by oligosaccharyltranferase (OST)
and dolichol-diphosphate (DolPP) is recycled by dolichol diphosphate
phosphatase encoded by DOLPP1. b The ALG6 gene encodes
Dol-P-Glc: Man9GlcNAc2-PP-dolichol α-1,3 glucosyltransferase
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Reagents
[2-3H]mannose (21.5 Ci/mmol), [6-3H]glucosamine
(37.7 Ci/mmol), [14C]-isopentyl diphosphate (56.6 mCi/
mmol), GDP-[14C]mannose (262 mCi/mmol), UDP-
[14C]glucose (348 mCi/mmol), UDP-[3H]GlcNAc (37 Ci/
mmol), ULTIMA GOLD and En3Hance were from
Perkin Life Sciences, Fr. RPMI 1640 medium, penicillin-
streptomycin (PS), fetal calf serum (FCS), OPTIMEM,
stealth RNAi, Lipofectamine RNAiMAX and the BCA™
Protein assay kit were from Thermo Scientific, Cergy Pon-
toise, FR. Peptide N-glycanase, bacitracin, Dowex resins
and protease inhibitors were obtained from SIGMA. The
tripeptide acetyl-Asn-Tyr-Thr-NH2 (Ac-NYT-NH2) was
purchased from Neosystem (Strasbourg, Fr.). TLC plates
were obtained from Merck (Darmstadt, Germany).
Cell culture
Skin biopsy fibroblasts [13] and HepG2 cells [14] were
cultivated as previously described.
Sequencing
For gene studies, signed informed consent protocols were
obtained from the parents. Ethics approval was from the
Comité de Protection des Personnes d’Île-de-France 2
(CPP IDF2). Targeted genomic Sanger sequencing of
several genes encoding proteins required for DLO biosyn-
thesis [PMM2 (NM_000303), ALG6 (NM_013339),
DPM1/2/3 (NM_003859, NM_003863, NM_153741), MP
DU1 (NM_004870), ALG2 (NM_033087), ALG7 (NM_
001382), ALG1 (NM_019109), ALG13/14 (NM018466,
NM_144988), ALG11 (NM_001004127)] and dolichol
biosynthesis (DHDDS, NM_020438) was performed on
DNA from fibroblasts derived from the patient. Primer
sequences are available upon request. DNA from the
parents was extracted from whole blood. Informed
consent was obtained from the parents. WES libraries
were prepared from 3 μg of genomic DNA, which was
sheared by ultrasonication using a Covaris S220 Ultraso-
nicator. The 51 Mb SureSelect Human All Exon kit V5
(Agilent technologies) was used for exome capture, and
sequencing of WES libraries was carried out on a
HiSeq2500 sequencer (Illumina) [15]. The mean
coverage depth was 244.51× ((98.22 > 30×; 99.74 > 15×
and 99.93 > 5×). After de-multiplexing, sequences were
aligned to the reference human genome hg19 using
the Burrows-Wheeler Aligner. Downstream processing
was carried out with the Genome Analysis Toolkit
(GATK), SAMtools, and Picard, following documented
best practices (https://www.broadinstitute.org/gatk/guide/
bp_step.php). Variant calls were made with the GATK
Unified Genotyper. The annotation process was based
on the ensembl database (75), dbsnp (135) EVS
(ESP6500SI-V2), 1000 genome (2011 05 21) and
EXAC (0.3). Variants were annotated and analysed
using the Polyweb software interface designed by the
Bioinformatics platform of University Paris Descartes
and Imagine Institute [16].
SiRNA-mediated down-regulation of DHDDS expression in
HepG2 cells
HepG2 cells were transiently transfected with 25 pmol
siRNA as previously described [14]. Three DHDDS-
targetting sense sequences (1; AACAAGUGCAGAU
CGCCCAGGACCC, 2; CCAACCCGUUCUGUGGCCA
GAGUAU, 3; CCGCUCUCCUCAUCCUGACAUCUUG)
and a medium GC non-targetting control sequence were
used. Cells were harvested 2, 4 and 6 days after
transfection.
RNA extraction, reverse transcriptase and reverse QPCR
RNA was extracted from fibroblasts or HepG2 cells
according to the manufacturer’s instructions (RNeasy
Plus Mini Kit, Qiagen). Reverse transcriptase reactions
were performed with 1 μg RNA using the Verso cDNA
synthesis kit (Thermo Scientific). RT PCR from cDNA
exon 3 to 7 of the DHDDS gene (primer sequences:
3SRT cactcacagggcttcaacaagc and 7RRT cggttggtatagagg-
cacttatc) was performed to confirm the splicing muta-
tion. QPCR was performed using the Absolute Blue
QPCR SYBER Green Mix Plus ROX vial (Thermo Scien-
tific) in a Roche Light Cycler 480. Primers for QPCR of
DHDDS and the HMBS housekeeping gene were pur-
chased from Qiagen. Primer sequences for the S14
housekeeping gene are as follows: S14 Sense:
TCACTCGGAAGAATACCATTTTTG, S14 Reverse;
CCGATTTCTGATTCTAACAGGAC.
Metabolic radiolabelling of cells
Confluent t25 cm2 flasks of fibroblasts were metabolic-
ally radiolabelled for 30 min in glucose free RPMI 1640
medium supplemented with 0.5 mM glucose and 2 %
dialysed foetal calf serum with 100 μCi [2-3H]mannose
[17]. SiRNA-treated HepG2 cells were radiolabeled for
30 min in 500 μL/well glucose-free RPMI 1640 medium
supplemented with 1 mM glucose, 2 mM fucose, 2 % di-
alyzed FCS and 50 μCi [2-3H]mannose [14].
Characterisation of dolichol linked oligosaccharides
and N-glycans
The following experimental procedures are described in
detail elsewhere [13]. Briefly, after washing with ice-cold
PBS, cells were scraped into 1 volume 100 mM Tris–
HCl (pH 7.4) containing 4 mM MgCl2. Two volumes of
methanol followed by 3 volumes of chloroform were
added to the aqueous cell suspension. After vigorous
shaking, the CHCl3 and MeOH/H2O phases were
separated by centrifugation and removed. The interface
pellet was extracted twice with 3 ml CHCl3:CH3OH:H2O
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(CMW, 10:10:3). The CHCl3 phase and CMW fractions
contain DLOs with small and large glycan chains,
respectively. Both fractions were dried under vacuum
and subjected to acid hydrolysis in 20 mM HCl. After
desalting on combined Dowex 1-X2 (acetate form)/
Dowex 50-X2 (H+ form) resins the released oligosac-
charides were dried under vacuum and, after pooling
fractions derived from the two organic phases described
above, were examined by thin layer chromatography
(TLC). N-linked oligosaccharides (NLOs) were released
from the interface protein pellets with PNGase F as
previously described [18].
Dolichol-P-mannose synthase and DHDDS assays
Total HepG2 and fibroblast membranes were prepared
as previously described [17]. Dolichol-P-mannose syn-
thase (DPMS) was assayed as reported previously in
either the presence or absence of DolP [18]. The same
membranes were used to assay DHDDS in either the
presence or absence of farnesyl diphosphate (FPP) [19].
For the latter assay, the 50 μL reactions were stopped by
the addition of 500 μL CHCl3/MeOH (2:1) before trans-
ferring the mixtures to 15 mL tubes containing 3.5 mLs
CHCl3/MeOH (2:1). Two phases were then obtained
after addition of 800 μL 4 mM MgCl2. The upper phase
was removed and discarded whereas the lower phase
was washed with 2 × 2 mLs 4 mM MgCl2/MeOH (1:1).
Radioactivity in the lower phase was then assayed by
scintillation counting.
Detection of endogenous Dol-P
Endogenous Dol-P levels were assayed in sealed ER
vesicles as previously described [20]. A sample of sealed
ER-vesicles (equivalent to 40 μg protein) was incubated
in 50 mM Tris–HCl (pH 7.5) containing: 250 mM
sucrose, bacitracin (400 μg/mL), acceptor peptide
(35 μM), AMP (4 mM) and CaCl2 and MgCl2 (5 mM) in
a total volume 30 μl. The reaction mixture was incu-
bated for 10 min at 37 °C. GDP-[14C]Man (3 μM) was
added and the mixture was incubated for 2 min at 37 °C.
After solvent extraction, radioactivity was assayed in
the organic phase by scintillation counting. The assay
was also performed in the absence of the synthetic
acceptor peptide as a negative control. Blanks, without
sealed ER-vesicles, were made for each condition.
Thin layer chromatography
Desalted DLOs and NLOs were resolved on silica-coated
plastic TLC plates developed for 18 h in a mobile phase
of propan-1-ol: acetic acid: water (3:3:2). After drying
the plates, radioactive components were visualized by
fluorography after spraying with En3Hance.
Protein expression in skin biopsy fibroblasts
and HepG2 cells
Proteins were extracted using a lysis buffer containing
20 mM Tris–HCl, 150 mM NaCl, 1 % TX-100, 1 %
protease and phosphatase inhibitors, and subjected to
SDS-PAGE using NuPage 4–12 % Bis-Tris gels (Fisher-
Thermo Scientific). The following primary antibodies were
used: anti- ICAM-1 sc-107 (Santa Cruz), anti-PDI (Cell
Signaling), anti-ATF-6α (F-7) sc-166659 (Santa Cruz),
anti-p-PERK (Thr 981) sc-32577 (Santa Cruz), anti-NgBR
IMG-5342-A (Imgenex), anti-Calnexin 610823BD (BD
Transduction Laboratories), anti-GRP75 BiP ab-21685
(Abcam), anti-Actin (I-19) sc-1616 (Santa Cruz).
Complementation of RER2-deficient S. cerevisiae with
wild-type and mutant human DHDDS forms
True clone DHDDS (SC321506, NM-205861; 1) was
mutated with QuickChange site-directed mutagenesis kit
(Stratagene) in K42E and W64X and then subcloned
into the yeast p416TEF plasmid [21]. Wt RER2 was
obtained by cloning PCR from yeast DNA in plasmid
pCR2.1 (TA cloning) and then subcloned into p416TEF.
The mutated DHDDS was tested in the RER2-TET-off
strain cultivated in the presence of 0.3 μM doxycycline.
Yeast strains in which the RER2 (rer2DR), ALG14
(alg14DR), ALG13 ((alg13DR) and ALG7 (alg7DR) genes
are under the control of the TET repressor were culti-
vated, alongside a parental strain, in the presence of
increasing concentrations of doxycycline for two over-
night passages in order to induce gene down regulation.
During the second passage, culture growth was mea-
sured by turbidometry, and inhibition of growth with
respect to that seen in the absence of doxycycline was
calculated. Subsequent to cultivation of alg14DR and
rer2DR cells in either the absence or presence of 1.0
and 0.3 μg/mL doxycycline, respectively, as described
above, cell extracts [22] were submitted to SDS-PAGE
and Western Blot using an antibody directed to
carboxypeptidase Y (CPY).
Results
Glycosylation profile of plasma glycoproteins
Figure 2a shows Western blotting of the plasma
glycoproteins α1-antitrypsin (AAT), transferrin (TF),
haptoglobulin (HAPTO) and orosomucoid (OROSO)
derived from the patient (P), a patient diagnosed with
PMM2-CDG and a normal subject (N). The patient
manifests additional AAT, HAPTO and OROSO gly-
coforms of inferior molecular weight reflecting hypo-
glycosylation [23].
Analysis of protein N-glycosylation in patient fibroblasts
Metabolic radiolabelling of skin biopsy fibroblasts with
[2-3H]mannose revealed that cells from the patient
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generated elevated levels of truncated DLO possessing
oligosaccharides bearing 5-9 residues of mannose as well
as fully mannosylated species containing 1–2 residues of
glucose (Fig. 2b). N-glycan (NLO) analysis also revealed
truncated species bearing 4-8 residues of mannose. The
experiment showed in Fig. 2b is representative of several
radiolabeling experiments: in some experiments the
truncated species were more apparent and in others less
so and, more generally, this phenotype gradually became
less apparent as a function of cell passage number. As
the metabolic radiolabelling procedure is carried out in
the presence of low glucose concentrations, which is
known to favour the appearance of truncated DLO, we
investigated the role of the extracellular glucose concen-
tration on the appearance of truncated DLO in two cell
populations derived from separate skin biopsies obtained
from the patient. It was noted that both cell populations
behaved similarly and that when radiolabeling was
performed in the presence of 2 mM glucose (instead of
the usual 0.5 mM glucose) truncated DLO were still
observed (results not shown). To conclude, oligosac-
charide profiles did not point to an obvious block in the
dolichol cycle. In addition to truncated DLO, it was
noticed that the ratio of the quantity of radioactivity
associated with NLO to that associated with DLO was
high in cells from the patient compared either to control
cells or those from other patients with CDG-I (Fig. 2c).
Mutations found in DHDDS gene
Routine targeted Sanger sequencing of several genes
encoding proteins required for DLO biosynthesis (PMM2,
ALG6, ALG7, ALG13/14, ALG1, ALG2, DPM1/2/3,
DOLK MPDU1, and ALG11) did not reveal potential
disease causing variants. The patient was found to be
homozygous for the c.911 T > C (p.F304S) ALG6 variant
(see Fig. 1b) that occurs in about one third of the popu-
lation and does not cause CDG, but as will be discussed
later, has been reported to be associated with severe
disease signs in patients whose glycosylation pathway is
otherwise compromised. While sequencing genes required
for dolichol biosynthesis, two mutations in the DHDDS
gene were found in DNA from the patient (Fig. 3a). After
sequencing DNA from the parents it was found that the
father harboured a nonsense mutation c.192G >A
(p.W64X) in exon 4 (Fig. 3a; upper panel), and the mother
possessed a splicing mutation (c.441-24A >G) in intron 5
(Fig. 3a; lower panel) that creates a cryptic donor splice
site (with score of 0.99 rather than 0.65 for the normal
exon 6 donor site) leading to: i) loss of exon 6, ii) a 63 base
insertion into intron 5 (Fig. 3b), iii) a premature stop:
c.440_543del102ins63 (p.C148EfsX11).
Complementation of RER2-deficient S. cerevisiae with
wild-type and mutant human DHDDS forms
Both mutations potentially lead to the generation of
severely truncated proteins devoid of the isopentenyl
pyrophosphate-binding domain (Fig. 3c). A yeast com-
plementation strategy was used to test the functionality
of the truncated DHDDS(W64X) protein. In the yeast S.
cerevisiae, the DHDDS gene is encoded by RER2 and the
rer2Δ strain is not viable. RER2 function in S. cerevisiae
can be evaluated using the TET-off system in which the
RER2 gene is invalidated upon addition of doxycycline
to the culture medium as shown in Fig. 4a. The data
shows that down-regulation of RER2 causes striking
growth retardation that is more pronounced than that
Fig. 2 Analysis of serum glycoproteins and N-glycosylation intermediates
in fibroblasts. a SDS PAGE and Western Blot of serum proteins from a
control subject (N), a patient diagnosed with phosphomannomutase
2-deficiencey (PMM2-CDG) and the patient described here (P). Antibodies
towards α1-antitrypsin (AAT), transferrin (TF), haptoglobulin (HAPTO) and
orosomucoid (OROSO) were used to probe the blots. The numbers to
the right of the images indicate glycoforms with 0, 1 and 2 N-glycans.
b Fibroblasts derived from a control subject (N) and the patient (P) were
metabolically radiolabeled with [2-3H]mannose and oligosaccharides
derived from dolichol linked oligosaccharides (DLO) and glycoproteins
(NLO) were resolved by TLC. The abbreviations used are: Man4-8GlcNAc2;
M4–8, Glc0-3Man9GlcNAc2; G0-3M9. c Fibroblasts derived from three normal
subjects (Ctrls) and five patients diagnosed with the indicated CDG I
subtypes were metabolically radiolabeled and, the quantity of
radioactivity associated with DLO and pronase-solubilised glycoproteins
(N-glycan) was assayed by scintillation counting. The results are
expressed as ratio of radioactivity associated with N-glycans/radioactivity
associated with DLO
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observed when genes required for early steps in DLO
biosynthesis (ALG7, ALG13 and ALG14) are down-
regulated in the same way. As shown in Fig. 4b, this
growth reduction is accompanied by the appearance of
hypoglycosylated carboxypeptidase Y (CPY), which is a
well-known marker for N-glycosylation in S. cerevisiae.
The functionality of the DHDDS(W64X) variant was
tested in the RER2-TET-off strain cultivated in the
presence of 0.3 μM doxycycline. Under these conditions,
as shown in Fig. 4b, both growth and CPY N-glycosy-
lation were restored when the RER2-TET-off strain was
transduced with either wild type RER2 or wild type
human DHDDS, but not with plasmids containing either
DHDDS(W64X) or the DHDDS(K42E) variant that is
associated with retinitis pigmentosa.
Reduced DHDDS gene expression and biological activity
in cells from the patient
The DNA sequencing data suggests that cells from the
patient should manifest reduced DHDDS expression.
The intronic mutation inherited from the mother does
not exclude utilization of the normal splice site so some
full length DHDDS mRNA is expected in cells from the
patient. Full length DHDDS mRNA was quantitated in
Fig. 3 Genomic sequencing and RT-PCR of mRNA transcripts. a Genomic DNA sequencing of exon 4 (father) and intron 5 (mother) showing the nonsense
mutation (c.192G > A p.W64X) in exon 4, and the splicing mutation (c.441-24A >G) in intron 5. b RT PCR from cDNA exon 3 to 7. An alternative transcript
without exon 6 exists in all subjects. c The domains of the DHDDS protein that contain the isopentenyl diphosphate (IPP) and farnesyl diphosphate (FPP)
binding sites are indicated along with the region containing the active site (vertical bar). The mutation seen in the father leads to a mRNA containing a
premature stop codon which if translated would lead to a severely truncated protein (W64X) missing the IPP binding site. Translation of the mother’s
variant mRNA would lead to a severely truncated protein (p.Cys148GlufsX11) containing 11 new amino acids (grey box) before the stop codon
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the skin biopsy fibroblasts from the patient and a normal
subject, and, as shown in Fig. 5a, the patient possessed
only 20–25 % normal DHDDS mRNA level. DHDDS
activity in crude microsomal preparations derived from
cells from the patient was found to be 35 % of that
found in those of cells from normal subjects (Fig. 5b and
c). By contrast, dolichol-P-mannose synthase (DPMS)
activity was found to be similar in the two microsome
preparations (Fig. 5d).
Reduced dolichol-phosphate levels in sealed microsomes
derived from cells of the patient
The DolP pool available for DLO biosynthesis was
estimated in either the absence or presence of a syn-
thetic acceptor peptide (Acetyl-Asn-Tyr-Thr-NH2: NYT)
that is known to provoke DolP recycling in sealed
microsomes [20]. Addition of NYT to sealed micro-
somes causes DLO to be discharged: yielding glyco-
peptide and DolPP. DolPP phosphatase (DOLPP1, see
Fig. 1) converts DolPP into DolP, which can then be
quantitated as Dol-P-[14C]Man after addition of GDP-
[14C]Man and by allowing DPMS action (that occurs at
the same levels in microsomes derived from cells of the
patient and control subject, Fig. 5d). Bacitracin com-
plexes DolPP and incubations in the absence or presence
of this antibiotic allow estimations of both DolPP-, and
DolP-dependent Dol-P-[14C]Man production. As shown
in Fig. 5e, bacitracin inhibits Dol-P-[14C]Man production
even in the absence of NYT indicating Dol-PP produc-
tion via the presence of endogenous substrates for OST.
Dol-P-[14C]Man generation in the presence of bacitracin
reveals a pre-existing DolP pool that, in microsomes
from the patient, appears to be reduced by ~67 %
compared to the control. Finally, it can be seen that
microsomes from the patient also demonstrate lower
NYT-provoked Dol-P-[14C]Man synthesis. The ensemble
of these data demonstrates a deficit in the quantity of
DolP available for synthesis of Dol-P-[14C]Man in the
patient’s cells. In order to evaluate the consequences of
the reduced DolP levels in the patient’s cells, the glyco-
sylation status of ICAM was examined. Hypoglycosy-
lated ICAM is rapidly degraded and this has been shown
to yield low steady state levels of this protein in type I
CDG cells [24]. Data presented in Fig. 5f indicate that
although the ICAM level is low in the patient’s cells, this
level is within the range of ICAM expression in the
control cell lines. Protein hypoglycosylation in type I
CDG may lead to increases in protein misfolding, ER
stress and initiation of the Unfolded Protein Response
(UPR) [25]. However, the level of the ER stress marker
calnexin (CNX) is within the range displayed by the
control cells. Interestingly, there is an inverse correlation
between ICAM and CNX expression in both control
and patient cells. The reason for the variable ICAM
expression even within the control cell population is
unknown but could be due to the different growth char-
acteristics or passage number of the different cell lines.
ATF46α is a UPR signaling protein [26], and when
unfolded proteins accumulate in the ER the expression
of full length ATF46α (Fig. 4f, ER; 90 kD) is increased as
well as its proteolytic cleavage to generate the 57 kD
Fig. 4 Complementation of rer2-deficient yeast with human DHDDS
transcripts. a (left panel). Yeast strains in which the RER2 (rer2DR),
ALG14 (alg14DR), ALG13 (alg13DR) and ALG7 (alg7DR) genes are under
the control of the TET repressor were cultivated, alongside a parental
strain, in the indicated concentrations of doxycycline and inhibition of
growth with respect to that seen in the absence of doxycycline was
calculated. (Right panel) Subsequent to cultivation of alg14DR and
rer2DR cells in either the absence or presence of 1.0 and 0.3 μg/mL
doxycycline, respectively, as described above, cell extracts were
submitted to SDS-PAGE and Western Blot using an antibody directed
to carboxypeptidase Y (CPY). The migration positions of different CPY
glycoforms are indicated to the left of the image. b (upper panel) The
rer2DR strain was transformed with wild type RER2, wild type DHDDS,
as well as the DHDDS(W64X) and DHDDS(K42E) variants and the empty
vector. Cell growth was measured (OD 600nm) in duplicate
transformants. (Lower panel) CPY glycosylation was examined
in one of these duplicate cultures
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nuclear from (N) [26]. The ER form of ATF46α is
expressed at a higher level in the patient’s cells than in
both control cells, and those from other CDG-I patients.
However, this increased expression was not accom-
panied by increased proteolytic cleavage to generate the
active nuclear form of the protein (Fig. 5f ).
Knock-down of DHDDS expression in HepG2 cells
The data presented above demonstrate the presence of
mutations in the DHDDS gene that lead to: 1) reduced
DHDDS mRNA levels, 2) reduced DHDDS activity, 3)
reduced DolP levels, and 4) small but significant changes
in DLO/N-glycan profiles in metobolically radiolabeled
Fig. 5 Evaluation of the consequences of DHDDS mutations in fibroblasts. a Quantitation of DHDDS cDNA generated from mRNA derived from
fibroblasts obtained from two cell populations from the patient (P and P’), a normal subject (N) and whole blood cell extracts from the father (F) and
mother (M). QRT-PCR using either ribosomal protein S14 (S14) or hydroxymethylbilane synthase (HMBS) as housekeeping genes was performed.
b DHDDS activity was assayed using farnesyl diphosphate (FPP) as acceptor. c After subtracting background values (− FPP) from the data points, the
initial slopes of the curves shown in (b) and two other similar experiments were estimated. The values (SlopeP/SlopeN) × 100 are plotted (solid circles).
SlopeN is set at 100 % for each experiment (open circles). d Dol-P-Man synthase (DPMS) activity was measured in the same microsome preparations as
used in (b) using GDP-[14C]mannose and DolP (DP) as acceptor. e Measurement of endogenous DolP levels in microsomes prepared from fibroblasts
derived from the patient (P) and a normal subject (N). Incubations were carried out with GDP-[14C]Man in the absence or presence of the glycosylation
acceptor peptide (NYT) and bacitracin as indicated. The specific activity of the GDP-[14C]Man is used to calculate the pmoles Dol-P-Man recovered from
the organic phase after stopping the reactions. f Extracts of fibroblasts from three control subjects, the patient (P), and patients diagnosed with ALG12-
CDG (Patient 2) and DPM2-CDG (Patient 3) were subjected to SDS-PAGE and Western Blot. The blots were probed with antibodies directed
towards intercellular adhesion molecule-1 (ICAM), calnexin (CNX), activating transcription factor 6 alpha (ATF6α) and actin
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fibroblasts derived from the patient. In order to deter-
mine whether or not reduced DHDDS expression could
lead to the changes in early steps of the N-glycosylation
pathway that were noted in the cells from the patient,
human hepatocellular carcinoma HepG2 cells were
transfected with siRNA duplexes targetting DHDDS. As
shown in Fig. 6a, DHDDS mRNA expression was
decreased by three DHDDS-targetting duplexes (1-3)
compared to the non-targetting duplex (nt), and
siRNA(1) was the most efficient at reducing DHDDS
expression. SiRNA(2) provoked an increase in non
adherent cells (not shown), a reduction in protein asso-
ciated with adherent cells (Fig. 6b), and reduced protein
synthesis as measured by [14C]leucine incorporation into
precipitable cellular proteins (Fig. 6c). Because
siRNA(1) provoked more effective DHDDS mRNA
down-regulation than siRNA(3) and siRNA(2) mani-
fested toxicity not apparent with the other duplexes,
the former duplex was selected for the following
experiments. In order to assay DHDDS activity in
Fig. 6 Down-regulation of DHDDS expression in HepG2 cells. HepG2 cells were transfected with three siRNA targeting DHDDS or a control
non-targetting siRNA (nt) and were harvested 4 days later. a Cellular mRNA was extracted and DHDDS cDNA was quantitated by qRT-PCR. b Total
adherent cell protein was assayed. c Cells were radiolabeled with [14C]leucine for 30 min, and radioactivity recorded in precipitated cellular proteins
was calculated per mg protein and these values were expressed as a percentage of that found in cells transfected with the control non-targetting
siRNA. d DHDDS activity was measured in the three cell populations. e HepG2 cells were mock transfected (None), or transfected with either the
control non-targetting siRNA (nt) or siRNA(1) targeting DHDDS, and at 2, 4 and 6 days post transfection the cells were metabolically radiolabeled with
[2-3H]mannose. Radioactivity associated with DLO (upper panel) and glycoproteins (NLO: middle panel) was measured as described in the legend to
Fig. 2c, and the ratio of incorporation of radioactivity into NLO to that into DLO is shown in the lower panel. f Oligosaccharides released from DLO
were resolved by TLC and visualized by fluorography. Regions corresponding to the migration positions of the indicated oligosaccharides were eluted
from the plate and assayed by scintillation counting. The abbreviations are as follows: G3-1; Glc3Man9GlcNAc2, M9-2; Man9-2GlcNAc2
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HepG2 cells that were transfected with siRNA(1), cells
were harvested 4 days post transfection and crude micro-
somal fractions were prepared. Data shown in Fig. 6d indi-
cates a 50 % reduction in DHDDS activity in cells treated
with DHDDS-targetting siRNA(1) compared to that found
in cells treated with the non-targetting siRNA (nt) or
sham transfected cells (None). Next, cells were metabo-
lically radiolabeled with [2-3H]mannose as described for
Fig. 2b. As shown in Fig. 6e, transfection of the cells with
the DHDDS-targetting siRNA(1) reduced radiolabel
incorporation into DLO (upper panel) without strikingly
affecting the quantity of radioactivity associated with
N-glycans (middle panel). The resulting high ratio of
[2-3H]DLO/[2-3H]N-glycan (lower panel) in the DHDDS-
down-regulated cells is similar that seen with the fibro-
blasts derived from the patient (Fig. 2c). TLC examination
of the DLO structures generated under the different
conditions demonstrates the presence of various truncated
DLO associated with DHDDS down-regulation at days 4
and 6 post-transfection (Fig. 6f). Finally, down-regulation
of DHDDS in HepG2 cells did not lead to changes in the
expression of ICAM, calnexin and ATF46α (results not
shown). To summarize, as was noted in fibroblasts from
the patient, DHDDS down-regulation in HepG2 cells
provokes the appearance of truncated DLO and an
elevated [3H]DLO/[3H]N-glycan ratio.
Whole exome sequencing
The clinical phenotype of the patient reported here
resembles that of other CDG-I patients and contrasts
with the retinitis pigmentosa phenotype of the first
reported DHDDS-deficient patients. This different pheno-
type could be explained by the presence of a mutation in
another gene that regulates N-glycosylation, or the asso-
ciation of DHDDS mutations with mutations in genes that
regulate N-glycosylation. Sanger sequencing revealed the
patient to be homozygous for the c.911 T > C (p.F304S)
ALG6 variant (see Fig. 1b) that does not cause CDG, but
is associated with severe disease signs in patients who
have mutations in other genes of the N-glycosylation
pathway. In order to look for other potentially disease
causing or disease modifying variants, whole exome
capture and next-generation sequencing (WES) on an Illu-
mina platform was performed on DNA from fibroblasts of
the patient. After filtering out variants occurring at > 1 %
in human population data banks (the c.911 T > C
(p.F304S) ALG6 variant was detected but filtered out
because it occurs at a frequency of 20-30 %), and selecting
those associated with glycosylation or dolichol meta-
bolism pathways, two genes were found with two
variants: DHDDS and TNKS1 (Tables 1 and 2). TNKS1
(Tankyrase, TRF1-Interacting Ankyrin-Related ADP-Ribose
Polymerase) functions include NAD+-dependent ADP-
ribosyltransferase activity. Poly-ADP-ribosyltransferases are
involved in various processes such as Wnt signaling,
telomere length maintenance and vesicle trafficking [27]. In
certain situations, the chromosomal location of the TNKS1
gene (8p23.1) is linked to a form of monogenic diabetes
[28]. Despite being lean and in other respects normal,
TNKS1-deficient mice display hyperphagia and altered fatty
acid metabolism without liver steatosis [28]. WES also
identified several heterozygous variants in genes of the N-
glycosylation pathway (Table 2) including ALG8, ALG9,
DDOST, MPDU1, ALG6, and STT3A. Even though single
mutations in these genes do not cause CDG, the possibility
that reduced activity/expression of the proteins that they
encode could amplify the phenotype caused by reduced
DHDDS expression cannot be excluded. The possibility of
further CDG gene variants hiding in an intron or poorly
covered region during WES cannot be excluded, but it was
found that for the 26 genes presently known to underlie
CDG, WES coverage was at least 30×.
Discussion
This case is of considerable interest because other
patients so far described with mutations in the DHDDS
gene present with a mild clinical picture restricted to
retinitis pigmentosa [11, 12, 29]. The present patient
showed a fatal clinical syndrome accompanied with
hypoglycosylated serum glycoproteins and truncated
DLO species, pointing to CDG-I. Two mutations in
DHDDS leading to 20–25 % DHDDS mRNA expression
and 35 % residual DHDDS activity were found. In
accordance with these data microsomes derived from
the patient’s cells revealed low levels of DolP. As our
studies progressed, and the passage number of the fibro-
blasts increased, we noted a gradual disappearance of
the glycosylation phenotype. Although it is not clear
why this should occur, it is possible that as the cells
become less metabolically active their glycosylation
requirements are reduced and there is less strain on the
dolichol cycle. The disappearance of the glycosylation
phenotype, and the fatal outcome in this case, made it
no longer feasible to try to normalize either the
abnormal DLO profile or [2-3H]mannose incorporation
into DLO by transfecting cells from the patient with
wild-type hDHDDS. In an alternative approach to
investigate the origin of the biochemical phenotype,
DHDDS expression was down regulated in HepG2 cells.
To date, there have been no attempts to knockdown
DHDDS expression in mice or mammalian cells in vivo.
It was noted that whereas DHDDS-down regulation in
HepG2 cells provoked an 80–90 % reduction in DHDDS
RNA, only a 50 % reduction in DHDDS activity could be
detected. This result was surprising and raises the
possibility of an alternative mechanism for dolichol
biosynthesis that is relatively more important in HepG2
cells than in fibroblasts. Alternative dolichol biosynthetic
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routes postulated previously [30, 31] remain contro-
versial [32]. Nevertheless, such a route might explain the
shorter dolichol chain lengths that have been observed
in NGBR- and DHDDS-deficient patients [10, 33]. Here
we demonstrate that siRNA-mediated knockdown of
DHDDS did not reduce the incorporation of [2-3H]-
mannose into glycoproteins, but did reduce strikingly
the incorporation of [2-3H]mannose into DLO, and
provoked a transient increase in the proportion of
truncated DLO species (Man6-8GlcNAc2-PP-dolichol).
One explanation for the occurrence of truncated DLO in
DHDDS-deficient cells with reduced DolP is that the
synthesis of Dol-P-Man and Dol-P-Glc are more
adversely affected than Dol-PP-GlcNAc. This would lead
to a DLO profile similar to that seen in MPDU1-CDG
where the ability of these two precursors to contribute
to DLO elongation is compromised [34]. Alternatively,
the slightly shorter dolichol chains that have been shown
to occur in previously described DHDDS- and NGBR-
deficient patients may also hinder Dol-P-Man and Dol-
P-Glc utilization. The mechanism underlying the para-
doxical apparent increase in incorporation of radioactiv-
ity into N-glycans with respect to that incorporated into
DLO is also not clear. One explanation might be that
the reduced DolP pool size could lead to a higher
specific activity of the radioactive DPM and DLO pools
compared to control cells. Accordingly, assuming that
protein synthesis rates are similar and that the DLO
pools are not limiting in control and DHDDS-deficient
cells then a higher incorporation of radioactivity into N-
glycans might be expected. An alternative hypothesis for
the inability of DHDDS down regulation to inhibit the
incorporation of radioactivity into N-glycans despite
reducing radioactivity associated with DLO is that the
DLO pool required for protein glycosylation is a sub
pool of total DLO, and that this sub pool is less
dependent upon DHDDS than the remaining DLO. To
summarise, in both cells from the patient and DHDDS-
deficient HepG2 cells, changes in the incorporation of
[2-3H]mannose into DLO and N-glycans along with
changes in the DLO profiles were detected. Therefore it
is concluded that the biochemical phenotype of cells
from the patient is compatible with reduced DHDDS
expression.
The previously described patients with mutations in
the DHDDS gene that present only with retinitis
pigmentosa [11, 12, 29], do not present with serum
glycoprotein hypoglycosylation. In these patients serum
and urine dolichols are abnormal [33]. Serum and urine
samples from our patient were not available. The
DHDDS ortholog, RER2, is an essential gene in yeast,
Table 1 Whole exome sequence filtering
SNVsa Variations Genes
All variants 9061 6301
Unknown or known variants <1 %
(dbSNP132/1 K genome/EVS ExAC)
and in-house database filtering (929)b
785 861
Glycosylation genes
Dolichol related genes
19
3
19
3
Gene(s) with two mutated alleles 2 2
aSNVs single nucleotide variants
bdbSNP132: http://www.ncbi.nlm.nih.gov/SNP/
1 K genome; 1000 genomes (http://www.1000genomes.org/), EVS; Exome
Variant Server (http://evs.gs.washington.edu/EVS/), ExAC; http://
exac.broadinstitute.org/, in-house database filtering; variant excluded if already
seen at the homozygous state in 929 exomes performed in the platform
Table 2 .Glycosylation or dolichol related genes with mutated alleles
Gene SNPa Type of mutationb Frequency data if already describedc
DHDDS c.192G > A (p.W64X) Stop -
c.441-24A > G (p.C148EfsX11) Intron (splice) ExAC: 0.00001663
TNKS c.1945G > A (p.D649N) Missense
(Polyphen pathogen, SIFT benign)
-
c.899-16362A > T Intron/ncRNA -
ALG8 c.1068C > G (p.P356=) Exon synonymous -
ALG9 c.-37-77G > A Intron -
DDOST c.679A > G (p.I227V) Missense
(Polyphen and SIFT benign)
ExAC: 0.00004444
MPDU1 c.393C > T, p.V131 = (rs79286384) Exon synonymous Av. he: 0.004
ExAC: 0.0007853
ALG6 c.987 + 43 T > C (rs181709997) Intron Av. he: 0.003
ExAC: 0.003458
STT3A c.88 + 131 T > C (rs191172467) Intron Av. he: 0.001+/−0.024
ExAC: no data
aGenomic positions are on UCSC genome Browser (hg19)
bPolyphen : http://genetics.bwh.harvard.edu/pph/, SIFT: http://sift.jcvi.org/
cAv. he: average heterozygosity (source dbSNP) or allele frequency ExAC
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and DOLK-CDG, SRD5A3-CDG and NGBR-CDG pa-
tients, who have mutations in other genes required for
the de novo biosynthesis of dolichol, present with mod-
erate to severe multisystemic manifestations [5, 10, 35].
Several explanations are possible for the differences in
these DHDDS-CDG phenotypes.
First, the K42E mutation, associated with isolated
retinitis pigmentosa, is perhaps not particularly dam-
aging. Functional glycosylation studies and DHDDS
assays have not been performed in fibroblasts from these
patients, so no comparison can be made with the
findings in cells from the present patient. Nevertheless,
we report here that wild-type hDHDDS, but not
hDHDDS(K42E), is able to normalise both impaired
growth and carboxypeptidase Y hypoglycosylation in
RER2-deficient S. cerevisiae. Interestingly, we present
data indicating that doxycycline-induced knockdown of
other essential yeast glycosylation genes (ALG7, ALG13
and ALG14) has much less impact on S. cerevisiae
growth than down-regulation of RER2. This observation
suggests that the RER2-dependent dolichol pool is
required for important cellular functions other than
protein N-glycosylation, or that RER2 itself has a role in
yeast homeostasis independent of its role in dolichol
production. Although the hDHDDS(K42E) variant is
unable to complement growth or N-glycosylation defects
in S. cerevisiae, its ability to support N-glycosylation in
mammalian/human cells maybe quite different due to
the fact that efficient dolichol biosynthesis by the
hDHDDS-encoded protein requires the hNGBR-encoded
protein [4, 10, 36]: a complex between hDHDDS(K42E)
and the yeast NgBR ortholog (nus1) may not be as
productive as that comprising both human proteins. More
recently, however, it has been demonstrated that mem-
branes derived from nus1Δrer2Δyeast complemented with
hDHDDS(K42E) and wild-type hNGBR display about
30 % the activity of those derived from the same strain
complemented with wild-type hDHDDS and hNgBR [10].
Therefore hDHDDS(K42E) does not support efficient
DHDDS activity.
Second, the reduced DHDDS activity caused by the
K42E variant may not be too serious for cells (apart from
those in the retina). However, reduced expression of the
DHDDS protein may be far more serious. DHDDS
knockdown in fertilized zebrafish eggs caused primarily
retinal photoreceptor degeneration, but, depending on
the degree of knockdown, provoked other phenotypic
changes that suggest roles for DHDDS are not restricted
to retinal photoreceptor maintenance in this organism.
Accordingly, reduced DHDDS expression may be more
damaging than normal expression of the inactive
hDHDDS(K42E) variant, potentially suggesting that
DHDDS has important functions that are independent
of its DHDDS activity. Nevertheless, an understanding
of the impact of DHDDS knockdown on mammalian
physiology will have to await the generation of mice
models. The DHDDS protein forms a complex with the
NgBR to form the fully active dehydrodolichol diphos-
phate synthase activity. NgBR also forms a complex of
unknown function with the Nogo-B protein, and a
complex with the Niemann-Pick C2 protein (NPC2) that
is known to regulate cholesterol metabolism. NGBR
knockout is embryonically lethal in mice and NGBR-
deficient cells, derived from either patients with muta-
tions in NGBR or mouse embryonic fibroblasts derived
from conditional NGBR−/− mice, display 10-17 %
residual DHDDS activity, reduced ICAM expression and
about 50 % reduction in [2-3H]mannose incorporation
into glycoproteins [10]. Accordingly, one of the conse-
quences of reduced DHDDS protein expression, that
is independent of reduced enzyme activity, might be
an excess of “free” NgBR that could deregulate
cholesterol metabolism or pathways that depend on
the Nogo-B protein.
Third, Sanger sequencing revealed that the patient was
homozygous for the ALG6(F304S) variant, which is
more frequent in PMM2-CDG patients with severe
disease than in those with moderate symptoms [37]. The
ALG6(F304S) variant is not as efficient at comple-
menting ALG6-deficient yeast as the wild type allele
[38], but is not thought to cause CDG because it occurs
in 27–33 % of the population, and 4–6 % of the popu-
lation are homozygous for this variant [37, 39, 40]. DLO
analyses in fibroblasts derived from the patient did
reveal accumulations of Man9GlcNAc2-PP-dolichol
above control levels (Fig. 2b), but other DLO species
accumulated to a greater extent, and this DLO profile is
not indicative of ALG6-CDG. WES of our patient
revealed two variants in the tankyrase 1 (TNKS1) gene
along with heterozygous variants in other genes (ALG6,
ALG8, ALG9, DDOST, MPDU1, and STT3A) required
for N-glycosylation. A role for these variants in the fatal
outcome of this disease cannot be excluded.
Conclusions
We describe a patient presenting with severe multi-
system disease associated with DHDDS deficiency. As
retinitis pigmentosa is the only clinical sign in pre-
viously reported cases of DHDDS deficiency our data
broaden its phenotypic spectrum. This case adds to
those in which the ALG6(F304S) variant is associated
with a severe/fatal disease presentation.
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